CITI/CALL/GILEAD SCIENCES/95/0.1/20.06.24

CITI/CALL/GILEAD SCIENCES/95/0.1/20.06.24 Share Price

Warrant

DE000KG57CA7

Market Closed - Deutsche Boerse AG
- ^EUR	-

Current year

-98.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart CITI/CALL/GILEAD SCIENCES/95/0.1/20.06.24

Latest news about GILEAD SCIENCES, INC.

Gilead and Kite Pharma Celebrates Pride Month	19/06	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit from Earlier Lines of Treatment	17/06	AQ
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06	CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Citi
WKN	KG57CA
ISIN	DE000KG57CA7
Date issued	05/07/2022
Strike	95 $
Maturity	Today (1 Days)
Parity	10 : 1
Emission price	0.12 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company